Onco-Innovations Appoints Dr. John Mackey to Scientific & Clinical Advisory Board
Onco-Innovations (CBOE CA:ONCO) has appointed Dr. John Mackey, Professor Emeritus in Oncology at the University of Alberta, to its Scientific and Clinical Advisory Board. Dr. Mackey brings extensive experience in oncology, clinical trials, and drug development, having previously served as Director of the Clinical Trial Unit at Cross Cancer Institute and Executive Director of TRIO.
Dr. Mackey's credentials include co-founding Pacylex Pharmaceuticals, serving as CEO of illumiSonics, holding 12 patents, and co-authoring over 300 peer-reviewed publications. His expertise will support Onco's PNKP inhibitor program development, particularly in clinical strategy and trial methodology.
Onco-Innovations (CBOE CA:ONCO) ha nominato Dr. John Mackey, Professore Emerito di Oncologia all'Università dell'Alberta, nel suo Scientific and Clinical Advisory Board. Il Dr. Mackey apporta un'ampia esperienza in oncologia, sperimentazioni cliniche e sviluppo di farmaci, avendo ricoperto in passato il ruolo di Direttore della Clinical Trial Unit al Cross Cancer Institute e di Executive Director presso TRIO.
Tra i suoi titoli, il Dr. Mackey è co-fondatore di Pacylex Pharmaceuticals, è stato CEO di illumiSonics, detiene 12 brevetti e ha co-autore di oltre 300 pubblicazioni peer-reviewed. La sua competenza sosterrà lo sviluppo del programma inibitore di PNKP di Onco, con un contributo particolare nelle strategie cliniche e nella metodologia degli studi.
Onco-Innovations (CBOE CA:ONCO) ha nombrado a Dr. John Mackey, Profesor Emérito de Oncología en la Universidad de Alberta, en su Scientific and Clinical Advisory Board. El Dr. Mackey aporta una amplia experiencia en oncología, ensayos clínicos y desarrollo de fármacos, habiendo sido anteriormente Director de la Clinical Trial Unit en el Cross Cancer Institute y Executive Director de TRIO.
Entre sus credenciales, el Dr. Mackey cofundó Pacylex Pharmaceuticals, fue CEO de illumiSonics, posee 12 patentes y ha coautor de más de 300 publicaciones revisadas por pares. Su experiencia apoyará el desarrollo del programa inhibidor de PNKP de Onco, especialmente en la estrategia clínica y la metodología de los ensayos.
Onco-Innovations (CBOE CA:ONCO)는 앨버타 대학교 암학 명예교수인 Dr. John Mackey를 자사의 과학 및 임상 자문위원회(Scientific and Clinical Advisory Board)에 임명했습니다. Mackey 박사는 임상시험 및 약물개발을 포함한 광범위한 암 치료 경험을 보유하고 있으며, 과거 Cross Cancer Institute의 Clinical Trial Unit 소장과 TRIO의 Executive Director를 역임했습니다.
Mackey 박사의 이력으로는 Pacylex Pharmaceuticals 공동창업, illumiSonics CEO 역임, 12건의 특허 보유 및 300편 이상의 동료심사 논문 공저 등이 있습니다. 그는 Onco의 PNKP 억제제 프로그램 개발에 대해 임상 전략과 시험 설계 분야에서 중요한 지원을 제공할 예정입니다.
Onco-Innovations (CBOE CA:ONCO) a nommé Dr. John Mackey, professeur émérite d'oncologie à l'Université de l'Alberta, à son Scientific and Clinical Advisory Board. Le Dr Mackey apporte une vaste expérience en oncologie, essais cliniques et développement de médicaments ; il a précédemment dirigé la Clinical Trial Unit du Cross Cancer Institute et a été Executive Director de TRIO.
Parmi ses qualifications, le Dr Mackey est cofondateur de Pacylex Pharmaceuticals, a été PDG d'illumiSonics, détient 12 brevets et est coauteur de plus de 300 publications évaluées par des pairs. Son expertise soutiendra le développement du programme d'inhibiteurs de PNKP d'Onco, notamment sur la stratégie clinique et la méthodologie des essais.
Onco-Innovations (CBOE CA:ONCO) hat Dr. John Mackey, Emeritus-Professor für Onkologie an der University of Alberta, in sein Scientific and Clinical Advisory Board berufen. Dr. Mackey bringt umfassende Erfahrung in Onkologie, klinischen Studien und Wirkstoffentwicklung mit und war zuvor Direktor der Clinical Trial Unit am Cross Cancer Institute sowie Executive Director bei TRIO.
Zu seinen Qualifikationen zählt die Mitgründung von Pacylex Pharmaceuticals, die Tätigkeit als CEO von illumiSonics, der Besitz von 12 Patenten und die Mitautorenschaft von über 300 peer‑reviewten Publikationen. Seine Expertise wird die Entwicklung des PNKP-Inhibitorprogramms von Onco insbesondere in klinischer Strategie und Studiendesign unterstützen.
- Addition of highly experienced oncology expert with extensive clinical trial expertise
- Dr. Mackey brings direct experience in advancing novel therapies from early-stage to commercialization
- Strategic appointment aligns with company's PNKP inhibitor program development goals
- None.
VANCOUVER, BC / ACCESS Newswire / September 5, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H)(WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce the appointment of Dr. John Mackey, Professor Emeritus in the Department of Oncology at the University of Alberta, to its Scientific and Clinical Advisory Board. His expertise will support Onco's efforts in aligning translational research with clinical execution, particularly as the Company progresses toward later-stage development of its PNKP inhibitor program.
Dr. Mackey has extensive experience in oncology, clinical trials, and cancer drug development. He previously served as Director of the Clinical Trial Unit at the Cross Cancer Institute and as Executive Director of Translational Research in Oncology (TRIO), a not-for-profit academic clinical research organization responsible for interventional cancer trials involving more than 22,000 participants1 globally.
He is a co-founder of Pacylex Pharmaceuticals, a biotechnology company developing therapies targeting N-myristoyl transferases, currently in Phase II international trials. He is also the CEO of illumiSonics, which is developing Microcellular Laser Imaging (MLI) technology for molecular histology. Additional initiatives include founding SMHeartCard, a personal emergency medication carriage system, and co-developing CWTA, a statistical method for analyzing multiple health states in clinical trials. Across these ventures, Dr. Mackey has been directly involved in advancing novel therapies from early-stage development through to clinical evaluation and commercialization, providing relevant experience for Onco's translational and commercial ambitions.
Dr. Mackey holds 12 patents and has co-authored over 300 peer-reviewed publications covering a range of topics, including membrane transporter biochemistry, oncology clinical trials, cancer diagnostics, physical activity as an intervention for cancer patients, and statistical methodologies. He is a Fellow of the Canadian Academy of Health Sciences.
In his role on the Scientific & Clinical Advisory Board, Dr. Mackey will contribute his expertise in clinical development, trial methodology, and translational oncology. His responsibilities will include advising on clinical strategy related to the Company's PNKP Inhibitor Technology (NP/A83) and other ongoing research programs.
"Dr. Mackey's work has consistently bridged discovery research with clinical implementation, particularly in areas where novel mechanisms require thoughtful trial design and regulatory navigation. His direct experience with first-in-class oncology therapeutics and leadership across academic and biotech environments aligns closely with the development path for our PNKP inhibitor program," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
Who is Dr. John Mackey and what is his role at Onco-Innovations (ONNVF)?
What experience does Dr. Mackey bring to Onco-Innovations (ONNVF)?
How will Dr. Mackey contribute to Onco-Innovations' (ONNVF) development programs?
What are Dr. Mackey's achievements in the biotech industry?
